Vir Biotechnology (VIR) is experiencing a surge of +58% pre-market due to a significant strategic partnership with Astellas concerning its prostate cancer ...
DURHAM, N.C. and BEIJING and SAN FRANCISCO and CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Brii Biosciences (“Brii Bio”), Vir Biotechnology, Inc. (Nasdaq: VIR), and VBI Vaccines Inc. (Nasdaq: ...
Vir Biotechnology, Inc. VIR announced that it has dosed the first patient in the phase II MARCH study which is evaluating VIR-2218 in combination with VIR-3434 for the treatment of patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results